We have recently presented a model of human adrenal medullary histogenesis that incorporates all neural crest-derived lineages (chromaffin, sustentacular, and ganglionic) known to compose this tissue. To determine if neuroblastomas correspond to the arrested maturation of embryonal adrenal medullary cells, we evaluated the expression of adrenal medullary developmental markers in 81 neuroblastoma tumors. We found that patterns of chromaffin-related gene expression in these tumors correlated exactly with the patterns observed during maturation of adrenal medullary cells (P2 < 10 '). In a multivariate Cox proportional hazards analysis of developmental marker expression and other well-recognized prognostic variables, evidence of maturation along a fetal ganglionic lineage, as monitored by HNK-1 immunoreactivity (relative risk of 6.42, P2 = 0.0001), and age at diagnosis (relative risk of 5.05, P2 = 0.0042) were independent and significant prognostic indicators ofpatient survival. These studies demonstrate that neuroblastomas correspond to embryonal adrenal medullary cells arrested at recognizable stages during development, and that evidence of maturation along a fetal ganglionic lineage appears to have major importance in predicting patient survival. (J.
Introduction
Neuroblastoma, a pediatric tumor arising in tissues derived from the embryonal neural crest, most frequently occurs at known sites of the sympathetic peripheral nervous system ( 1 ). This tumor exhibits remarkable heterogeneity in its histopathologic appearance, biochemical properties, and response to chemotherapy (2) (3) (4) (5) (6) (7) (8) . Although a number of prognostic indicators of patient survival have been described for this tumor, including age of the patient at diagnosis, stage, amplification of the N-myc oncogene, the Shimada histopathologic classification, expression of neuropeptide Y, and serum ferritin levels (6, (9) (10) (11) (12) (13) , the biological basis for the significance ofthese prognostic factors remains poorly understood.
Clinical, histopathologic, and laboratory findings suggest that altered regulation of neural crest cell differentiation can play a role in the pathogenesis of neuroblastoma (14) (15) (16) (17) (18) . For example, the remarkably high incidence of neuroblastoma in situ reported in autopsy series of infants dying from causes unrelated to cancer suggests that many of these in situ tumors spontaneously remit, perhaps by differentiating to mature adrenal medullary tissues ( 14, 15) . Similarly, stage IVS neuroblastoma tumors, a variant of stage IV disease presenting itself in patients < 1 yr of age who have small primary tumors and remote disease confined to liver, skin, and/or bone marrow, often undergo spontaneous tumor regression, occasionally resulting in residual, benign ganglioneuromas (19) (20) (21) .
We therefore investigated the possibility that neuroblastoma tumor cells may correspond to the arrested differentiation of adrenal medullary progenitor cells found during histogenesis of this tissue. In previous studies, we identified and characterized a series of markers defining discrete stages during the maturation of adrenal medullary chromaffin cells and distinguishing cells ofthis lineage from other neural crest-derived adrenal precursors that differentiate along either the sustentacular or ganglionic lineage ( 17, 22, 23) . We found that neuroblastoma cell lines express these chromaffin markers in patterns found during development, suggesting that these tumor cells correspond to adrenal medullary chromaffin progenitor cells that are arrested in differentiation ( 17) . In this study, we examined the expression of these lineage-related markers in neuroblastoma tumor specimens and evaluated the clinical implications of such a developmental analysis.
Methods
Tumor specimens. 81 formalin-fixed, paraffin-embedded neuroblastoma tumor specimens obtained from Children's Hospital of Philadelphia were used in this study. These (24) . However, P values < 0.01 are highly suggestive of an association.
Survival durations were computed from the date the patient was diagnosed with neuroblastoma until the date ofdeath or last follow-up. Probabilities of survival as a function of time were determined by the Kaplan-Meier method (25) . The Mantel-Haenszel procedure (26) was used to evaluate the usefulness ofeach prognostic factor (i.e., age, stage, markers ofdifferentiation, Shimada grade, and serum ferritin levels) in predicting patient survival. This procedure was also used to determine the significance of the difference between a pair of Kaplan-Meier curves. The Cox proportional hazards modeling technique (27) (27) .
Results
We have previously presented a model ofhuman adrenal medullary histogenesis that incorporates the chromaffin, ganglionic, and sustentacular lineages known to constitute the parenchymal cells of the adult adrenal medulla ( Fig. 1) just before birth. HNK-1 marks a fetal ganglionic lineage that appears to undergo developmental cell death at -24 wk of gestation (23) . This antibody also marks a small percentage of chromaffin adrenal medullary cells beginning 4-8 mo after birth, but does not react with most chromaffin cells until after 5 yr of age (23) . In neuroblastoma tumor specimens, HNK-1 immunoreactivity is almost uniformly associated with ganglionic differentiation, based on the lack of chromaffin marker expression in these cell types, as well as the localization of HNK-1 staining to tumor-derived neurophil (our unpublished data).
To determine whether neuroblastoma tumor cells correspond to fetal adrenal medullary progenitor cells that have matured along chromaffin, ganglionic, or sustentacular lineages, we examined the expression of adrenal medullary lineage-related markers in 81 tumor samples obtained from surgical specimens of untreated neuroblastoma patients at the Children's Hospital of Philadelphia between 1972 and 1987. The clinical characteristics of this patient population closely reflect those previously reported for patients with neuroblastoma (Tables I  and III) (6, 9) . The proportion ofpatients with advanced stage tumors in this cadre is decreased, since the diagnosis ofstage IV neruoblastoma can often be made by bone marrow examination alone, and primary tumor specimens were therefore not available for all such patients.
We observed in these specimens that the expression ofdevelopmentally regulated markers associated with either the chro-maffin or sustentacular lineages were unrelated to most previously described prognostic indicators of patient survival, including the age of the patient at diagnosis, serum ferritin level, and histopathologic classification of the tumor (Table I) Although the tumor specimens presented in Fig. 2 are composed of cells that have differentiated along a single lineage, other tumor specimens were composed of groups of cells that expressed markers from different adrenal medullary lineages. Populations of chromaffin and nonchromaffin tumor cells tended to be localized to different areas of the tumor specimen (data not shown). Of the 66 tumors that expressed lineage-related markers, 30% expressed markers from a single lineage, whereas 70% expressed markers from multiple lineages (data not shown). Since neuroblastoma is thought to be a clonal tumor (29) , this finding suggests that some neuroblastoma tumor cells retain the plasticity to differentiate along multiple developmental pathways.
Most neuroblastoma cell lines appear to correspond to adrenal medullary chromaffin progenitor cells arrested at one of several different stages of maturation (17) . We therefore evaluated the expression of several developmentally regulated chromaffin markers in neuroblastoma tumor specimens. Presented in Table II are the numbers of tumor specimens that expressed either markers of early chromaffin adrenal medullary maturation, TH and/or CGA, or a marker of mature embryonal chromaffin adrenal medullary cells, B2M. All B2M positive tumor specimens also expressed the early chromaffin markers. Significantly, there were no examples of tumor specimens that expressed B2M without coexpression of early chromaffin markers (P2 < 10-5), the single combination that would have been inconsistent with the pattern of markers expressed during normal development. This finding indicates that chromaffin markers are not expressed in a random fashion. Rather, the observed pattern of gene expression closely mimics that found during embryonal development of chromaffin adrenal medullary cells.
These data indicate that neuroblastoma tumor cells may correspond to the arrested differentiation of adrenal medullary precursors at different points along maturational pathways. We reasoned that the maturational stage or the lineage to which the tumor corresponds may correlate with distinct tumor cell properties, including various features of the tumor that are of clinical significance. We evaluated this possibility by examining the prognostic value of lineage-related marker expression, as well as other previously described prognostic indicators, including age at diagnosis, stage, serum ferritin level, and the Shimada classification. The N-myc copy number and DNA ploidy analysis were not available for most of these patients. As summarized in Table III , we found that evidence of differentiation along a fetal ganglionic lineage, as marked by HNK-1 immunoreactivity, was a significant prognostic variable in this univariate analysis, comparable to these other prognostic indicators. The expression of other developmentally regulated markers was not of prognostic significance.
To evaluate if HNK-1 was an independent prognostic indicator of patient survival, we performed a Cox proportional hazards analysis including patient age at diagnosis, stage, serum ferritin level, and lineage-related marker expression in the models. As the Shimada classification incorporates the age of the patient at diagnosis in its formulation, it could not be considered independent of age, and therefore was not included in this analysis. The most predictive model we could identify (model chi square value of 44.25 with three degrees of freedom) included only three variables: HNK-1 immunoreactivity, with a relative risk of6. 42 risk of 5.05 for those patients > 12 mo vs those < 12 mo of age (P2 = 0.0042); and serum ferritin which had less significance, with a relative risk of 2.20 for those patients having high levels (P2 = 0.0513). The independent prognostic significance of age at diagnosis and HNK-1 immunoreactivity is consistent with the lack of correspondence between age and evidence of differentiation along the ganglionic lineage, as presented in Table I .
The Kaplan-Meier survival curves in Fig. 3, A and B, illustrate the independent prognostic significance of both age at diagnosis and HNK-1 immunoreactivity. The survival of patients > 1 yr of age at diagnosis, a widely recognized indicator ofpoor prognosis, is presented in (A) according to the presence or absence of HNK-1 immunoreactivity in their tumor specimens. Patients with HNK-1 positive tumors had a better prognosis than patients with HNK-1 negative tumors (P2 < 106).
The 5-yr survival of patients with HNK-1 positive tumors was 81%, whereas the 5-yr survival of patients with HNK-1 negative tumors was 12%. Similarly, the survival of patients with HNK-1 negative tumors, a bad prognostic category, is presented in Fig. 3 B according to the age ofthe patient at diagnosis. Patients < 1 yr of age had a better prognosis than older patients (P2 = 0.0008). The 5-yr survival of patients < 1 yr of age was 82%, whereas the 5-yr survival of patients > 1 yr of age was 12%.
In contrast to HNK-l and age of the patient at diagnosis, stage was not an independent predictor of survival in our multivariate Cox proportional hazard analysis. This finding is illustrated by the Kaplan-Meier survival curves in (Fig. 3, C (30) , there is little evidence suggesting a correspondence between solid tumor cells and the cell types found during histogenesis oftissues in which such tumors arise. The availability of multiple chromaffin-related developmental markers made it possible to critically evaluate the hypothesis that neuroblastoma tumor cells correspond to the arrested differentiation of chromaffin adrenal medullary progenitor cells. As reported in Table II , we found no example ofchromaffin-related marker expression in neuroblastoma tumor specimens that deviated from the normal developmental pattern of gene expression. These findings indicate that chromaffin gene expression in neuroblastoma is not a stochastic process. Rather, these data strongly argue that some of the regulatory mechanisms that control chromaffin maturation in normal adrenal (Table III) . As illustrated in Fig. 3 , both age at diagnosis and HNK-1 immunoreactivity can independently distinguish subsets of good prognosis neuroblastoma patients from larger groups of high risk patients defined by use of either variable alone.
Many neuroblastoma tumors retain the plasticity to mature along multiple adrenal medullary lineages. Of the 66 tumors that expressed lineage-related markers, 70% contained different populations of cells expressing markers from two or more adrenal medullary lineages. Patients with HNK-l positive tumors had a good prognosis irrespective of the percentage of tumor cells expressing this marker or whether other tumor cells in the specimen were marker negative or had differentiated along chromaffin or sustentacular pathways (data not shown).
These data suggest that the biological significance of HNK-l immunoreactivity in predicting patient survival is the plasticity of tumor cells to mature along a fetal ganglionic lineage. This tumor plasticity may be mediated through intrinsic pathways characteristic of neural crest progenitor cells during embryogenesis (31, 32) , and may result from the presence of extrinsic modulators of neural crest cell differentiation (33, 34) . Several agents that can modulate adrenal medullary differentiation, including glucocorticoids (35) (36) (37) , fibroblast growth factor (38, 39) , and nerve growth factor (35) (36) (37) have been identified in model systems of neural crest maturation. In addition, the presence oflocal growth factors normally produced by the adrenal cortex, such as IGF-II, may also influence the proliferation and differentiation of neuroblastoma tumor cells (40) .
The association between HNK-1 immunoreactivity and improved patient survival suggests that therapeutic strategies to differentiate neuroblastoma tumors along a ganglionic lineage may be successful in modulating the therapeutic responsiveness of these tumors. In vitro studies using neuroblastoma cell lines indicate that some biological response modifiers, such as retinoic acid and dexamethasone, can modulate chromaffinrelated marker expression (41-42) (data not shown). Related studies may identify subsets of neuroblastoma patients whose tumor cells retain the plasticity to mature along a ganglionic pathway, suggesting a novel approach for the use of biological response modifiers to modulate tumor cell biology and render currently incurable patients sensitive to available antineoplastic therapies.
This developmental analysis of neuroblastoma also suggests a mechanism for the spontaneous regression of stage IVS tumors. In previous studies, we have reported that the number ofganglion progenitor cells in fetal adrenal glands dramatically falls after 24 wk of gestation (23) . Since many fetal ganglion cells have evidence of nuclear fragmentation at this developmental stage (data not shown), we believe that most fetal adrenal ganglion cells undergo developmental cell death. As presented in Table I , our analysis revealed that all nine stage IVS tumor specimens were HNK-1 positive compared to 37 of 72 non-stage IVS tumors, an association with near statistical significance in view ofthe numerous comparisons being made in this retrospective analysis (P2 = 0.0055). These data raise the possibility that the spontaneous remission of stage IVS disease may be related to mechanisms underlying the programmed cellular death of fetal adrenal medullary ganglion cells. The potential to induce tumor cells to undergo cell death might well be pursued in neuroblastoma.
The 
